Viewing Study NCT04415320


Ignite Creation Date: 2025-12-25 @ 4:11 AM
Ignite Modification Date: 2025-12-26 @ 3:09 AM
Study NCT ID: NCT04415320
Status: UNKNOWN
Last Update Posted: 2020-06-04
First Post: 2020-05-29
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Sponsor: Betta Pharmaceuticals Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module